Editas seeking valuation above $600M

Gene editing company Editas Medicine Inc. (Cambridge, Mass.) amended its proposed IPO on NASDAQ and plans to sell 5.9 million shares at $16-$18. At $17, it would raise $100.3 million and be valued at $606.9 million. Morgan Stanley, JPMorgan, Cowen and JMP Securities are underwriters.

Next year, the company hopes to begin a clinical study of its lead program, which applies its CRISPR/ Cas9 ( CRISPR-associated protein 9) genome editing platform to address Leber's congenital amaurosis (LCA) 10, a form of progressive blindness. ...